Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanwa licenses DPP-4 inhibitor to Choongwae

This article was originally published in Scrip

Executive Summary

Sanwa Kagaku Kenkyusho has licensed its pipeline DPP-4 inhibitor antidiabetic SK-0403 to Choongwae Pharma for development and commercialisation in South Korea. The Japanese firm, which is part of the Japanese pharmaceutical wholesaling group Suzuken, will receive undisclosed up-front, milestone and sales-based royalties as part of the deal. SK-0403 is currently in Phase II development in Japan, where it has just been licensed to Kowa for joint development and commercialisation.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts